Michael K Keng

Tran, V., Salafian, K., Michaels, K., Jones, C., Reed, D., Keng, M., & El Chaer, F. (2024). MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications. CURRENT HEMATOLOGIC MALIGNANCY REPORTS. doi:10.1007/s11899-024-00736-9

Garcia-Manero, G., Kazmierczak, M., Wierzbowska, A., Fong, C. Y., Keng, M. K., Ballinari, G., . . . Ades, L. (2024). Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study. LEUKEMIA RESEARCH, 140. doi:10.1016/j.leukres.2024.107480

Altman, J. K., Zuckerman, T., Koprivnikar, J., Mccloskey, J., Kota, V., Keng, M., . . . Rowe, J. M. (2023). Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study. BLOOD ADVANCES, 7(24), 7494-7500. doi:10.1182/bloodadvances.2023010943

Lantz, J., Pham, N., Jones, C., Reed, D., El Chaer, F., & Keng, M. (2024). Blinatumomab in Practice. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 19(1), 1-8. doi:10.1007/s11899-023-00714-7

Gulleen, E. A., Holte, S., Zhang, Y., Mbarusha, I., Mubiru, D., Pedun, B., . . . Phipps, W. (2023). Etiology of Fever and Associated Outcomes Among Adults Receiving Chemotherapy for the Treatment of Solid Tumors in Uganda. OPEN FORUM INFECTIOUS DISEASES, 10(11). doi:10.1093/ofid/ofad508

Garcia, J. S., Flamand, Y., Penter, L., Keng, M., Tomlinson, B. K., Mendez, L. M., . . . Soiffer, R. J. (2023). Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.. Blood, 141(15), 1884-1888. doi:10.1182/blood.2022017686

Van Galen, J., Maldonado, S., Grose, K., Bagley, F., Olivier, R., Van Hoose, J., . . . Volodin, L. (2023). Minimizing the risk of Clostridioides difficile infection as an early complication of autologous stem cell transplantation.. Antimicrobial stewardship & healthcare epidemiology : ASHE, 3(1), e158. doi:10.1017/ash.2023.424

Varadarajan, I., Pierce, E., Scheuing, L., Morris, A., El Chaer, F., & Keng, M. (2023). Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. ONCOTARGETS AND THERAPY, 16, 1-16. doi:10.2147/OTT.S274551

Robinson, E. D., Keng, M. K., Thomas, T. D., Cox, H. L., Park, S. C., & Mathers, A. J. (2022). Reducing Repeat Blood Cultures in Febrile Neutropenia: A Single-Center Experience. OPEN FORUM INFECTIOUS DISEASES, 9(11). doi:10.1093/ofid/ofac521

Pierce, E., Mautner, B., Mort, J., Blewett, A., Morris, A., Keng, M., & El Chaer, F. (2022). MRD in ALL: Optimization and Innovations. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 17(4), 69-81. doi:10.1007/s11899-022-00664-6

Ung, J., Tan, S. -F., Fox, T. E., Shaw, J. J. P., Vass, L. R., Costa-Pinheiro, P., . . . Loughran, T. P. (2022). Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. BLOOD REVIEWS, 55. doi:10.1016/j.blre.2022.100950

Courville, E. L., Shantzer, L., von Eckstaedt, H. C. V., Mellot, H., Keng, M., Sen, J., . . . El Chaer, F. (2022). Variant Acute Promyelocytic Leukemia Presenting Without Auer Rods Highlights the Need for Correlation with Cytogenetic Data in Leukemia Diagnosis. LABORATORY MEDICINE, 53(1), 95-99. doi:10.1093/labmed/lmab051

Riley, D. O., Schlefman, J. M., Von Eckstaedt, V. H. C. V., Morris, A. L., Keng, M. K., & El Chaer, F. (2021). Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 16(3), 314-324. doi:10.1007/s11899-021-00638-0

Isaac, K. M., Reed, D. R., Desai, R. P., Williams, E., Balkrishnan, R., Keng, M. K., & Ballen, K. K. (2021). Epidemiology of acute myeloid leukemia in Virginia: Excellent survival outcomes for patients in rural Appalachia. CANCER REPORTS, 4(4). doi:10.1002/cnr2.1354

Wages, N. A., Reed, D. R., Keng, M. K., Conaway, M. R., & Petroni, G. R. (2021). Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial. CLINICAL TRIALS, 18(3), 314-323. doi:10.1177/1740774520983484

Keng, M., Quinn, D., Cunningham, G., Bingham, J., Chiang, A., Eisinger, M., . . . Srivastava, P. (2020). ASCO Quality Training Program: A Five-Year Review. JCO ONCOLOGY PRACTICE, 16(10), 694-+. doi:10.1200/OP.20.00319

Reed, D. R., Sen, J. M., Pierce, E. J., Elsarrag, R. Z., & Keng, M. K. (2020). Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 26(5), 1200-1212. doi:10.1177/1078155220918006

El Chaer, F., Keng, M., & Ballen, K. K. (2020). MLL-Rearranged Acute Lymphoblastic Leukemia. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 15(2), 83-89. doi:10.1007/s11899-020-00582-5

Schaeffer, C. V., Moran, T. E., Keng, M. K., Bateman, H. R., & DeGeorge, B. R. J. (2020). Granulocytic Sarcoma A Rare Cause of Wrist Pain. ANNALS OF PLASTIC SURGERY, 85(1), 29-32. doi:10.1097/SAP.0000000000002315

Reed, D., Sen, J., Lassiter, K., Thomas, T., Harr, E., Daniels, E., & Keng, M. (2020). Prospective Initiative to Reduce Mucosal Barrier Injuries and Bloodstream Infections in Patients With Hematologic Malignancy Receiving Inpatient Chemotherapy. JCO ONCOLOGY PRACTICE, 16(3), E306-E312. doi:10.1200/JOP.19.00344

Mort, M. K., Sen, J. M., Morris, A. L., DeGregory, K. A., McLoughlin, E. M., Mort, J. F., . . . Keng, M. K. (2020). Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 26(3), 680-687. doi:10.1177/1078155219873014

Man, L., Sen, J., Giordano, J., McLoughlin, E., Morris, A., DeGregory, K., . . . Keng, M. (2019). Multidisciplinary Effort to Decrease Time From Admission to Chemotherapy on an Inpatient Oncology Unit. JOURNAL OF ONCOLOGY PRACTICE, 15(8), E728-E732. doi:10.1200/JOP.18.00281

Reed, D. R., Elsarrag, R. Z., Morris, A. L., & Keng, M. K. (2019). Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment. CANCER MANAGEMENT AND RESEARCH, 11, 8073-8080. doi:10.2147/CMAR.S162784

Reed, D. R., Pierce, E. J., Sen, J. M., & Keng, M. K. (2019). A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate. CANCER MANAGEMENT AND RESEARCH, 11, 8065-8072. doi:10.2147/CMAR.S190084

Morris, A. L., Naeem, M., Murray, T., Sen, J., Thomas, T., Daniels, E., . . . Keng, M. (2018). Establishing an Antifungal Program to Reduce Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Receiving Induction and Reinduction Chemotherapy. JOURNAL OF ONCOLOGY PRACTICE, 14(12), E770-E774. doi:10.1200/JOP.18.00307

Hathaway, L., Sen, J. M., & Keng, M. (2018). Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. PATIENT-RELATED OUTCOME MEASURES, 9, 329-337. doi:10.2147/PROM.S149420

Man, L. M., Morris, A. L., & Keng, M. (2017). New Therapeutic Strategies in Acute Lymphocytic Leukemia. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 12(3), 197-206. doi:10.1007/s11899-017-0380-3

Thomas, T., Reuss, J., Degennaro, G., Daniels, E., Li, J., Smolkin, M., & Keng, M. K. (2016). A prospective study of an inpatient febrile neutropenia clinical practice guideline in oncology patients.. J Clin Oncol, 34(7_suppl), 114. doi:10.1200/jco.2016.34.7_suppl.114

Keng, M. K., Thallner, E. A., Elson, P., Ajon, C., Sekeres, J., Wenzell, C. M., . . . Sekeres, M. A. (2015). Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department. JOURNAL OF ONCOLOGY PRACTICE, 11(6), 450-+. doi:10.1200/JOP.2014.002733

Ornstein, M. C., Mukherjee, S., Keng, M., Elson, P., Tiu, R. V., Saunthararajah, Y., . . . Sekeres, M. A. (2015). Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. LEUKEMIA & LYMPHOMA, 56(9), 2536-2542. doi:10.3109/10428194.2014.1003557

Nazha, A., Seastone, D. P., Keng, M., Hobson, S., Kalaycio, M., Maciejewski, J. P., & Sekeres, M. A. (2015). The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. LEUKEMIA & LYMPHOMA, 56(12), 3437-3439. doi:10.3109/10428194.2015.1041391

Keng, M. K., Wenzell, C. M., & Sekeres, M. A. (2013). A drug's life: the pathway to drug approval.. Clinical advances in hematology & oncology : H&O, 11(10), 646-655.

Keng, M. K., & Sekeres, M. A. (2013). Febrile Neutropenia in Hematologic Malignancies. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 8(4), 370-378. doi:10.1007/s11899-013-0171-4

Keng, M. K., & Sekeres, M. A. (2013). The race for survival in myelodysplastic syndromes. LEUKEMIA & LYMPHOMA, 54(2), 219-220. doi:10.3109/10428194.2012.726724

Ornstein, M., Mukherjee, S., Keng, M. K., Elson, P., Tiu, R. V., Saunthararajah, Y., . . . Sekeres, M. A. (2012). Vancomycin-Resistant Enterococcus (VRE) Bacteremia During Acute Myeloid Leukemia (AML) Induction Therapy Is an Independent Predictor of Poor Outcome. BLOOD, 120(21). doi:10.1182/blood.V120.21.1487.1487